Literature DB >> 20333608

Randomized comparative long-term survival study of endoscopic and thoracoscopic esophageal wall repair after NOTES mediastinoscopy in healthy and compromised animals.

A Fritscher-Ravens1, T Cuming, C F Eisenberger, M Ghadimi, A Nilges, P Meybohm, S Schiffmann, B Jacobsen, F Seehusen, H Niemann, W T Knoefel.   

Abstract

BACKGROUND AND STUDY AIMS: Natural orifice transluminal endoscopic surgery (NOTES) has not yet been widely adopted because of lack of suitable equipment and fear of possible serious complications, especially in the mediastinum. We compared endoscopic with thoracoscopic esophageal wall repair after full-thickness esophageal wall incision (FTEI) and NOTES mediastinoscopy in healthy versus compromised animals.
METHODS: After FTEI for mediastinoscopy, 24 pigs (12 healthy, 12 compromised) were randomly allocated to endoscopic or thoracoscopic repair (each arm of each group, n = 6). They were kept alive for 3 months after endoscopic closure with prototype T-anchor suturing or thoracoscopic repair.
RESULTS: FTEI and mediastinoscopy were uneventful in all as was the initial repair of the incision (mean repair times: thoracoscopic 65 +/- 3.2 minutes, endoscopic 52 +/- 5.1 minutes; P < 0.0005). Post procedure, all 12 healthy pigs thrived with no complications or deaths. Two compromised animals died during the preparation period, and had to be replaced. In the compromised group, during endoscopic repair, 2 / 6 pigs suffered from gastric reflux into esophagus and mediastinum; the repair was completed and the pigs kept alive; one subsequently died of mediastinitis, and in the other, autopsy showed a gastric abscess in the lower mediastinum. Regarding the compromised thoracoscopic subgroup, one animal died from mediastinitis and all had abscesses at or near the incision sites.
CONCLUSION: Transesophageal mediastinoscopy could be performed equally well as the transthoracic procedure, both in healthy and compromised animals. However, on follow-up, the compromised animals had worse outcomes, with more complications and two deaths (17 %), one in each arm. Georg Thieme Verlag KG Stuttgart.New York.

Entities:  

Mesh:

Year:  2010        PMID: 20333608     DOI: 10.1055/s-0029-1244019

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  6 in total

Review 1.  [Transesophageal/transgastric access for NOTES].

Authors:  A Fritscher-Ravens
Journal:  Chirurg       Date:  2010-05       Impact factor: 0.955

Review 2.  Novel treatment options for perforations of the upper gastrointestinal tract: endoscopic vacuum therapy and over-the-scope clips.

Authors:  Rudolf Mennigen; Norbert Senninger; Mike G Laukoetter
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

Review 3.  Natural orifice surgery in thoracic surgery.

Authors:  Yun-Hen Liu; Yen Chu; Yi-Cheng Wu; Chi-Ju Yeh; Chien-Ying Liu; Ming-Ju Hsieh; Hsu-Chia Yuan; Po-Jen Ko; Hui-Ping Liu
Journal:  J Thorac Dis       Date:  2014-01       Impact factor: 2.895

Review 4.  Asian perspectives in thoracic surgery: clinical innovation in Taiwan.

Authors:  Chao-Yu Liu; Chen-Sung Lin; Chia-Chuan Liu
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

5.  Comparative study of NOTES alone versus NOTES guided by a new image registration system for navigation in the mediastinum: a study in a porcine model.

Authors:  Henry Córdova; Raúl San José Estépar; Antonio Rodríguez-D'Jesús; Graciela Martínez-Pallí; Pedro Arguis; Cristina Rodríguez de Miguel; Ricard Navarro-Ripoll; Juan M Perdomo; Miriam Cuatrecasas; Josep Llach; Kirby G Vosburgh; Gloria Fernández-Esparrach
Journal:  Gastrointest Endosc       Date:  2013-01       Impact factor: 9.427

6.  Comparison of hemodynamic and inflammatory changes between transoral and transthoracic thoracoscopic surgery.

Authors:  Yen Chu; Chien-Ying Liu; Yi-Cheng Wu; Ming-Ju Hsieh; Tzu-Ping Chen; Ying-Kai Chao; Ching-Yang Wu; Hsu-Chia Yuan; Po-Jen Ko; Yun-Hen Liu; Hui-Ping Liu
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.